# Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects

> **NCT04637919** · PHASE1 · UNKNOWN · sponsor: **HK inno.N Corporation** · enrollment: 30 (estimated)

## Conditions studied

- Hand, Foot and Mouth Disease

## Interventions

- **BIOLOGICAL:** IN-B001 EV71 A dose
- **BIOLOGICAL:** IN-B001 CVA16 B dose
- **BIOLOGICAL:** IN-B001 Bivalent C dose
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04637919
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04637919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04637919, "Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04637919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*